Insider Selling: Artivion (NYSE:AORT) SVP Sells 977 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Price Performance

Shares of AORT traded up $0.38 during mid-day trading on Wednesday, hitting $28.77. 758,936 shares of the company were exchanged, compared to its average volume of 593,839. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a 50 day moving average of $23.79 and a 200-day moving average of $30.81. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -410.94 and a beta of 1.25.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The company had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Analysts expect that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AORT has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion in the third quarter valued at about $27,000. Rockefeller Capital Management L.P. boosted its holdings in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares during the last quarter. KBC Group NV purchased a new stake in shares of Artivion in the 4th quarter valued at approximately $65,000. Finally, First Horizon Corp increased its holdings in shares of Artivion by 199.4% during the 4th quarter. First Horizon Corp now owns 1,602 shares of the company’s stock worth $73,000 after buying an additional 1,067 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.